1310250-12-4

Basic information

• Product Name: Pyrazolo[1,5-a]pyriMidine-3-carbonitrile, 4,5-dihydro-7-hydroxy-5-oxo-
• Synonyms: Pyrazolo[1,5-a]pyriMidine-3-carbonitrile, 4,5-dihydro-7-hydroxy-5-oxo-;7-Hydroxy-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile
• CAS NO: 1310250-12-4
• Molecular Formula: C7H4N4O2
• Molecular Weight: 176.13226
• Mol File: 1310250-12-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyrazolo[1,5-a]pyriMidine-3-carbonitrile, 4,5-dihydro-7-hydroxy-5-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyriMidine-3-carbonitrile, 4,5-dihydro-7-hydroxy-5-oxo-(1310250-12-4)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyriMidine-3-carbonitrile, 4,5-dihydro-7-hydroxy-5-oxo-(1310250-12-4)

Safety Data

• Hazardous Substances Data: 1310250-12-4(Hazardous Substances Data)

Upstream product

• 16617-46-2 3-amino-4-cyano-2H-pyrazole 
• 105-53-3 diethyl malonate 
• 16617-46-2 3-Amino-4-cyanopyrazole 

Downstream Products

• 845895-95-6 5,7-dichloropyrazolo[1,5-a]pyrimidine-3-carbonitrile 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.

Erratum: Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: Discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach (Journal of Medicinal Chemistry (2012) 55 (6700-6715) DOI: 10.1021/jm300411k)

-